

Special Issue

Treatment of Lung Cancer

Message from the Guest Editors

The treatment of lung cancer, especially non-small cell lung cancer (NSCLC), has changed considerably in the last two decades. At the beginning of this century, standard chemotherapy consisted of various doublets, depending on the type of tumor (squamous, non-squamous), while there are also local differences. However, in general, the doublets consisted of gemcitabine/cisplatin, a taxane/cisplatin, and gemcitabine/pemetrexed. For these doublets, a number of potential predictive biomarkers have been investigated, usually focusing on the properties of the single drugs (e.g., drug metabolism, drug transport, DNA repair mechanism). This sometimes led to some extent of personalized therapy. However, with the recognition that many types of adenocarcinoma are addicted to a specific signaling pathway, new types of therapy, often called targeted therapy, have been introduced. This Special Issue covers all of these aspects in the treatment of lung cancer.

Guest Editors

Prof. Dr. Godefridus J. Peters

1. Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
2. Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland

Prof. Dr. Rafal Dziadziuszko

Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk Ul, Smoluchowskiego 17, 80-214 Gdańsk, Poland

Deadline for manuscript submissions

closed (10 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/166258

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)